Stories
Cannabis Gummies in India: Legal Status, Psychoactive Effects, and Product Verification Explained
- •India's NDPS Act defines cannabis by charas and ganja, excluding seeds and leaves not accompanied by flowering tops.
- •Cannabis-derived ingredients can be found in Ayurvedic formulations under separate regulations, requiring medical supervision.
- •THC is responsible for intoxicating effects, while CBD is generally non-intoxicating, but individual responses vary.
- •Cannabinoids interact with the endocannabinoid system, influencing pain, mood, and sleep, with evidence for specific medical uses.
- •Consumers should verify product legitimacy by checking licenses, ingredients, cannabinoid concentrations, and independent testing.
Key Questions Answered
India's NDPS Act defines cannabis as charas, which is separated cannabis resin, and ganja, meaning the flowering or fruiting tops of the plant. The law excludes seeds and leaves when they are not accompanied by the flowering or fruiting tops.
THC is primarily responsible for the intoxicating effects associated with cannabis, whereas CBD is generally considered non-intoxicating. However, full-spectrum products or CBD preparations can still affect alertness, cause sleepiness, or lead to dizziness depending on the dose and individual sensitivity.
Consumers should check the manufacturer's license details, batch information, exact ingredients, and cannabinoid concentrations rather than relying solely on front-of-pack labels. Experts also recommend looking for an independent certificate of analysis verifying testing for heavy metals, pesticides, and microbial contamination.
